Schizophrenia: A brain disease. II. Functional netiroimaging;La esquizofrenia: Una enfermedad cerebral. II. Neuroimagen funcional

Actas Espanolas de Psiquiatria

Volumn 28, Issue 1, 2000, Pages 31-39

  Crespo Facorro, B ^a,c   Arango, C ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Functional neuroimaging; PET; rCBE; Schizophrenia; Tomography

Indexed keywords

BRAIN; BRAIN CIRCULATION; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; METABOLISM; RADIOGRAPHY; REVIEW; SCHIZOPHRENIA;

BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033651578     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Raichle M, Grubb R, Gado M, Eichling J, Ter-Pergossina M. Correlation between regional cerebral blood flow and oxidative metabolism. Arch Neurol 1976; 33:523-6.
2. Andreasen NC. Brain imaging: applications in psychiatry. Washington DC: American Psychiatric Press; 1989.
3. Turner R, Jezzard P. Magnetic resonance studies of brain functional activation using echo-planar imaging. En: Thatcher RW, Hallet M, Zeffiro T, John ER, Huerta M, eds. Functional neuroimaging: technical foundations. San Diego: Academic Press; 1994.
4. Andreasen NC, Cohen G, Harris G, Cizadlo T, Parkkinen J, Rezai K, Swayze VW. Image processing for the study of brain structure and function: problems and programs. J Neuropsychiatry Clin Neurosci 1992;4: 125-33.
5. Berman KF, Weinberger DR. Functional localization in the brain in schizophrenia. En: Tasman A, Goldfinger SM, eds. Review of Psychiatry. Washington DC: American Psychiatric Press 1991;10: 24-59.
6. Buchsbaum MS, Hazlett EA. Positron Emission Tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 1998;24:343-64.
7. Berman KF, Weinberger DR. Cerebral blood flow studies in schizophrenia. En: Nasrallah H, Weinberger DR, editores. The neurobiology of schizophrenia. Amsterdam: Elsevier/NorthHolland Press; 1986. p. 277-307.
8. Velakoulis D, Panelis C. What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Aust NZ J Psychiatry 1996;30:195-209.
9. Bajc M, Medved V, Basic M, Topuzovic N, Babic D. Cerebral perfusion inhomogeneities in schizophrenia demonstrated with single photon emission computed tomography and 99Tcm-hexamethylpropyleneamineoxime. Acta Psychiatr Scand 1989;80:427-33.
10. Siegel BV, Buchsbaum M, Bunney WE, Gottschalk LA, Haier RJ, Lohr JB, et al. Cortico-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenics. Am J Psychiatry 1993;150:1325-36.
11. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49:959-65.
12. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-71.
13. Early TS, Reiman EM, Raichle ME, Spitznagel EL. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Nat Acad Sci USA 1987;84:561-3.
14. Kling AS, Metter EJ, Riege WH, Kuhl DE. Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am J Psychiatry 1986;143:175-80.
15. 15O positron emission tomography scanning in predominantly never treated acute schizophrenic patients. Lancet 1983;31:1446-52.
16. Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, et al. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 1989;28:119-23.
17. Buchsbaum MS, Potkin SG, Siegel BV, Lohr J, Katz M, Gottschalk LA, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992;49:966-74.
18. Wiesel FA, Wik G, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr Scand 1987;76:628-41.
19. DeLisi LE, Holcomb HH, Cohen RM, Pickar D, Carpenter W, Morihisa JM, et al. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 1985;5:201-6.
20. Szechtman H, Nahmias C, Garnett S, Firnau G, Brown GM, Kaplan RD, Clerghorn JM. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 1988;45:523-32.
21. Cleghorn JM, Szechtman H, Garnett ES, Nahmias C, Brown GM, Kaplan RD, Szechtman B. Apomorphine effects on brain metabolism in neuroleptic-naive schizophrenic patients. Psychiatry Res 1991;40: 135-53.
22. Buchsbaum MS. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia illness. Clin Neuroscience 1995;3:122-30.
23. Buchsbaum MS, Someya T, Teng YC, Abel L, Chin S, Najafi A, et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 1996;153:191-9.
24. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. Hypofrontality in schizophrenic patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-58.
25. Parellada E, Catafau AM, Bernardo M, Lomena F, Gonzalez-Monclus E, Setoain J. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting activation SPECT study. Psychiatry Res Neuroimaging 1994;55:131-9.
26. Weinberger DR, Berman KF, Zee RF. Psychologic dysfunction of dorsolateral prefrontal cortex in schizophrenia I. Regional blood flow evidence. Arch Gen Psychiatry 1986;43:114-24.
27. Gur RE, Pearlson GD. Neuroimaging in schizophrenia research. Schizophr Bull 1993;19:337-53.
28. Andreasen NC. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology. Science 1997;275:1586-93.
29. Frith CD. The cognitive abnormalities underlying the symptomatology and the disability of patients with schizophrenia. Int Clin Psychopharmacol 1995;10 (Supl 3):87-98.
30. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:348-57.
31. Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Boles Ponto LL, et al. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci USA 1996;93:9985-90.
32. Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary D, Watkins GL, Boles-Ponto LL, Hichwa RD. Recalling word list reveals «cognitive dysmetria» in schizophrenic patients. A PET study. Am J Psychiatry 1999;156:386-92.
33. Wiser AK, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto L, Hichwa RD. Dysfunctional cortico-cerebellar circuits cause «cognitive dysmetria» in schizophrenia. Neuroreport 1998;9:1895-9.
34. Frith CD, Friston KJ, Herold S, Silbersweig D, Fletcher P, Cahill C, et al. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry 1995;167: 343-9.
35. Ganguli R, Carter C, Mintun M, Brar J, Becker J, Sarma R, Nichols T, Bennington E. PET mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. Biol Psychiatry 1997;41:33-42.
36. Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC. Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. Biol Psychiatry 1994;35:3-15.
37. Carter CS, Mintun M, Nichols T, Cohen JD. Anterior cingulate gyrus dysfunction and selective attention deficit in schizophrenia. Am J Psychiatry 1997;154: 1670-5.
38. O'Leary D, Andreasen NC, Hurting R, Kesler ML, Rogers M, Arndt S, et al. Auditory attentional deficits in patients with schizophrenia. Brain Lang 1996;53: 633-41.
39. McGuire PK, Shah GMS, Murray RM. Increased blood flow in Brocka's area during hallucinations in schizophrenia. Lancet 1993;342:703-6.
40. McGuire PK, Silbersweig DA, Wright I, Murray RM, David AS, Frackowiak RSJ, Frith CD. Abnormal monitoring of inner speech: a physiologycal basis for auditory hallucinations. Lancet 1995;343:596-600.
41. David AS, Woodruff PWR, Howard R, Mellers JDC, Brammer M, Bullmore E, et al. Auditory hallucinations inhibit exogenous activation of auditory association cortex. Neuroreport 1996;7:932-6.
42. Kindermann SS, Karimi A, Symonds L, Brown GG, Jeste DV. Review of functional magnetic imaging in schizophrenia. Schizophr Bull 1997;27:143-56.
43. Volz HP, Gaser C, Hager F, Rzanny R, Mentzel HJ, Kreitschmann-Andermahr I, et al. Brain activation during cognitive stimulation with the Wisconsin Sorting Card Test. A functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res Neuroimaging 1997;75:145-57.
44. Yurgelun-Todd DA, Waternaux CM, Cohen BM, Gruber SA, English CD, Renshaw OF. Functional magnetic resonance imaging in schizophrenic patients and comparison subjects during word production. Am J Psychiatry 1996;153:200-5.
45. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 1974;50:425-62.
46. Volkow ND, Wolf AP, Van Gelder P, Brodie JD, Overall JE, Cancro R, Gómez-Mont F. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry 1987;144:151-8.
47. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997;349: 1730-4.
48. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997;349:1735-9.
49. Gur RE, Mozley D, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, et al. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 1995;52:657-67.
50. Musalek M, Podreka I, Walter H, Suess E, Passweg V, Nutzinger D, et al. Regional brain function in hallucinations: a study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients with auditory hallucinations, tactile hallucinations and normal controls. Compr Psychiatry 1989;30:99-108.
51. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ. Patterns of cerebral blood flow in schizophrenia. Br J Psychaitry 1992;160:179-86.
52. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Niethammer R. Structural and functional correlates of subsyndromes in chronic schizophrenia. Psychopathology 1995;28:38-45.
53. Dolan RJ, Bench CJ, Liddle PF, Friston KJ, Frith CD, Grasby PM, Frackowiak RSJ. Dorsolateral prefrontal cortex dysfunction in the major psychoses: symptom or disease specificity? J Neurol Neurosurg Psychiatry 1993;56:1290-4.
54. Paulman RG, Devous MD, Gregory RR, Herman JH, Jennings L, Bonte FJ, et al. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. Biol Psychiatry 1990;27:377-99.
55. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with FDG and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-30.
56. Kurachi M, Kobayashi K, Matsubara R, Hiramatsu H, Yamaguchi N, Matsuda H, et al. Regional cerebral blood flow in schizophrenic disorders. Eur Neurol 1985;24:176-81.
57. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995;378:176-9.
58. Cleghorn JM, Franco S, Szechtman B, Kaplan RD, Szechtman H, Brown GM, et al. Toward a brain map of auditory hallucinations. Am J Psychiatry 1992; 149:1062-9.
59. Busatto GF, David AS, Costa DC, Ell PJ, Pilowsky LS, Lucey JV, Kerwin RW. Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography. Psychiatry Res Neuroimaging 1995;61:255-64.
60. Notardonato H, Gonzalez-Avilez A, Van Heertum RL, O' Connell RA, Yudd AP. The potential value of serial cerebral SPECT scanning in the evaluation of psychiatric illness. Clin Nucl Med 1989;14:319-22.
61. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995;346:743-9.
62. Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug naive schizophrenics. Science 1986;234:1558-63.
63. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:213-9.
64. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-23.
65. Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365: 441-5.
66. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-6.
67. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentration: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-74.
68. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 1997;154:56-63.
69. Schröder J, Bubeck B, Demish S, Sauer H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Res 1997;68:125-31.
70. Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS, et al. Cognitive functioning and GA-BAA/benzodiazepine receptor binding in schizophrenia: a 123I-isomazenil SPET study. Biol Psychiatry 1998;43:107-17.
71. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6:869-72.
72. Smith GS, Schlosser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998;18:18-25.
73. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997;7:9-24.
74. Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992;160(Supl 17):30-3.
75. Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Rodenbeck A, et al. [123I] IBZM SPET analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment. Biol Psychiatry 1996;39:107-11.
76. Schröder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, et al. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: A follow-up study with tomography in the drug-naive and after neuroleptic treatment. Biol Psychiatry 1998;43: 660-5.
77. Goyer PF, Berridge MS, Morris ED, Semple WE, Compton-Toth BA, Schulz SC, et al. PET measurements of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 1996;37:1122-7.
78. Kapur S, Zipursky RB, Remington G, Jones C, Da Silva J, Wilson AA, Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998;155:921-8.
79. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
80. Andersson U, Erkenas SA, Hartvig P, Ulin J, Langston B, Haggstrom JE. Striatal binding of 11C-NMSP studied with positron emission tomography in patients with tardive dyskinesia: No evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect 1990;79:215-6.
81. Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc'h C, et al. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry 1989;52:1248-52.
82. Szymanski S, Gur RC, Gallacher F, Mozley LH, Gur RE. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism. Neuropsychopharmacology 1996;15:567-75.
83. Farde L, Mack RJ, Nyberg S, Halldin C. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindol in healthy subjects. Int Clin Psychopharmacol 1997;12(Supl 1):3-7.
84. Frith C. Disordered functional connectivity in schizophrenia? Psychol Med 1996;26:663-7.
85. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of schizophrenia. Schizophr Bull 1997;23:437-58.
86. Pearlson GD, Petty RG, Ross CA, Tien AY. Schizophrenia: A disease of heteromodal association cortex? Neuropsychopharmacology 1996;14:1-17.